Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.
You may also be interested in...
Disease-Awareness Ads Thrive In Regulatory No-Man’s Land
FDA says its hands are tied when it comes to curbing practices such as the testosterone ads its advisory committees have found problematic, but are the agency’s powers really that limited?
FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label
Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.
Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says
Inspire Pharmaceuticals gets a letter from FDA's Division of Drug Marketing, Advertising and Communications for a four-page professional journal ad for its bacterial conjunctivitis treatment AzaSite.